Form 4: Bionano Genomics Director Receives Stock Option Grant
Director Equity Grant
Director Kristiina Vuori was granted 9,149 stock options in Bionano Genomics, Inc. as part of standard equity compensation.
Summary
- Director Kristiina Vuori received a grant of 9,149 stock options on May 14, 2026.
- The options have an exercise price of $1.19 per share.
- The options are set to expire on May 13, 2036.
- Vesting occurs in equal monthly installments over 12 months, with full vesting guaranteed by the next annual stockholder meeting.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in nature.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Dilutive impact of new option grants on existing shareholders.
Risks
- Potential for future dilution if options are exercised.
- Market price volatility affecting the value of the granted options.
Future Outlook
The options vest over a 12-month period, incentivizing the director's continued service to the company.
Management Comments
- No specific management commentary provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise while aligning incentives with corporate performance.
Comparison to Industry Standards
- The grant structure follows standard industry practices for board compensation in small-cap biotech firms.
- Vesting schedules tied to annual meetings are common governance mechanisms to ensure director retention.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of stock options to a director under the 2018 equity incentive plan. | 05/14/2026 | Standard alignment of director compensation with company performance. |
Stakeholder Impact
- Minor dilution for existing shareholders upon potential future exercise of options.
Next Steps
- Vesting of options over the next 12 months.
- Potential exercise of options by the director upon vesting.
Key Dates
| Date | Description |
|---|---|
| 05/14/2026 | Transaction date of the stock option grant. |
| 05/13/2036 | Expiration date of the stock options. |
Keywords
Bionano Genomics, BNGO, Director Compensation, Stock Options, Insider Transaction, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.